Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Monday, March 11, 2019 at 4:00 PM to 4:30 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?


Currently submitted to: JMIR mHealth and uHealth

Date Submitted: Aug 9, 2019
Open Peer Review Period: Aug 12, 2019 - Sep 17, 2019
(closed for review but you can still tweet)

NOTE: This is an unreviewed Preprint

Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note “no longer under consideration” will appear above).

Peer-review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a “Peer-Review Me” button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.

Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).

Final version: If our system detects a final peer-reviewed “version of record” (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.

Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.

Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.

Development of A Mobile App “InCharge Health” to Improve Adherence to Hydroxyurea in Sickle Cell Disease: A User-centered Design Approach

  • Nicole Alberts; 
  • Sherif M. Badawy; 
  • Jason Hodges; 
  • Jeremie H. Estepp; 
  • Chinonyelum Nwosu; 
  • Hamda Khan; 
  • Matthew Smeltzer; 
  • Ramin Homayuni; 
  • Sarah Norell; 
  • Lisa Klesges; 
  • Jerlym S. Porter; 
  • Jane S. Hankins; 



Sickle cell disease (SCD) is an inherited blood disorder causing acute complications and chronic progressive end organ damage. SCD is associated with significant morbidity, early mortality and impaired health-related quality of life as well as increased acute healthcare utilization. Hydroxyurea is an FDA-approved medication that reduces disease complications, acute health-care utilization, and costs. However, adherence to hydroxyurea is suboptimal. mHealth interventions have the potential to assist with overcoming barriers to hydroxyurea adherence among patients with SCD but few examples exist that are specific to this population.


To design a mobile application (app) intervention for individuals with SCD to improve adherence to hydroxyurea, using a user-centered design that was informed by specific barriers to hydroxyurea adherence and utilization in this population.


The current study consisted of 4 phases. In Phase 1, individuals with SCD and health care providers participated in an Optimization Digital Workshop. In Phase 2, patients completed surveys pertaining to their interest in mHealth use, barriers and facilitators to hydroxyurea use, and health literacy. Phases 3 and 4 involved semi-structured interviews and focus groups, respectively – which used the Health Belief Model as the framework to investigate drivers of poor hydroxyurea adherence and to inform the development of an app prototype. In addition, in Phase 4, patients provided feedback on the preliminary app prototype and its features, which was in turn used to finalize the app prototype.


Barriers to hydroxyurea adherence were consistent with the literature and included forgetfulness and several specific thoughts and emotions associated with hydroxyurea use (e.g., fear of side effects, depression, stigma, hopelessness). In addition, more than half of participants reported potentially low health literacy. Preferred patient app features included seven key components (1) medication reminders/tracker, (2) disease education, (3) communication, (4) personalization, (5) motivation, (6) support during pain episodes, and (7) social support. Utilizing a user-centered design approach, data obtained from patients and providers were translated into features within the app, mapping to components of the Health Belief Model and the specific drivers of hydroxyurea adherence and matched the literacy level of the population and resulted in the development of a novel mobile app called InCharge Health.


The InCharge Health app, is a mHealth intervention developed with substantial input from users and mapping the Health Belief Model as the framework that guided the choice for its components. InCharge Health is a customized product for the SCD population aimed at optimizing medication adherence, with the end goal of improving quality of life and health outcomes among patients with SCD. The efficacy and implementation of the InCharge Health app as an mHealth intervention to promote hydroxyurea adherence will be tested in a future stepped-wedge multicenter trial for adolescents and adults with SCD. Clinical Trial: NCT03344900


Please cite as:

Alberts N, Badawy SM, Hodges J, Estepp JH, Nwosu C, Khan H, Smeltzer M, Homayuni R, Norell S, Klesges L, Porter JS, Hankins JS

Development of A Mobile App “InCharge Health” to Improve Adherence to Hydroxyurea in Sickle Cell Disease: A User-centered Design Approach

JMIR Preprints. 09/08/2019:14884

DOI: 10.2196/preprints.14884


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.